Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gateway-study: Gliadel implantation for newly diagnosed and recurrent glioblastoma
jRCTs051180159Phase 2Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carmustine, temozolomide and bevacizumab in glioblastoma (GBM) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Progression-free survival at 12 months (Stage 1), Overall survival (Stage 2) and 1 more. Started Aug 2015; status: active, not recruiting.
02
Drugs
carmustinetemozolomidebevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCTs051180159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180159.